Nevro (NVRO) Misses Q4 EPS by 11c, Revenues Beat; Offers FY19 Revenue Views Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Nevro Reports Fourth Quarter and Full Year 2018 Financial Results
February 21, 2019 4:10 PM ESTREDWOOD CITY, Calif., Feb. 21, 2019 /PRNewswire/ --Â Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today reported financial results for the fourth quarter and full year ended December 31, 2018.
2018 Accomplishments and Recent Highlights
Hired Michael Carter as Vice President, Global Sales to lead worldwide sales organization Launched Senza II: a smaller-footprint, advanced battery system with 10+ year life, and subsequently received FDA Approval for Conditional Full Body MRI Published a global registry of long-term... More